The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.
 
Minji Uh
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; IPSEN; Janssen Oncology; Lilly; Merck Sharp & Dohme; Novartis; Novocure; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck Sharp & Dohme; Pfizer; Roche; Takeda
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; iTeos Therapeutics Inc.; Janssen; Lilly Japan; Merck; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pharma Mar, S.A.; RIKEN GENESIS CO., LTD.; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca Japan; Bayer; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Haihe Biopharma Co., Ltd.; Janssen; Lilly Japan; Syneos Health
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Life Technologies (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Precision Medicine Asia Co., Ltd. (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Benjamin J. Solomon
Honoraria - Amgen (Inst); AstraZeneca; Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); BeiGene; Bristol-Myers Squibb (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Janssen (Inst); Lilly; Merck Sharp & Dohme; Pfizer (Inst); Roche/Genentech (Inst); Takeda
Research Funding - Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Keunchil Park
Honoraria - BeiGene; INCYTE
Consulting or Advisory Role - ABION; AstraZeneca; Daiichi Sankyo; Geninus; IMBdx; JNJ
Speakers' Bureau - Boehringer Ingelheim
 
Ernest Nadal
Honoraria - Apollomics; Roche/Genentech; Transgene
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; Merck Serono; MSD; Pfizer; Pierre Fabre; Qiagen; Roche; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche
 
Emilio Bria
Consulting or Advisory Role - AstraZeneca; BMS Brazil; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca; Roche
Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche
 
Claudio Martin
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
 
Jair Bar
Stock and Other Ownership Interests - Causalis
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Immunai (Inst); MSD (Inst); Novartis (Inst); Oncohost (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Justin Williams
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Tarun Puri
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Jian Li
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Boris K. Lin
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly
 
Caicun Zhou
Leadership - IASLC BOD
Honoraria - Alice; Amoy Diagnostics; Anheart Therapeutics; Boehringer Ingelheim; CStone Pharmaceuticals; Hengrui Therapeutics; Innovent Biologics; Lilly; Luye Pharma; Merck Sharpe and Dohme; MSD; QiLu Pharmaceutical; Roche; Sanofi; TopAlliance BioSciences Inc
Consulting or Advisory Role - Amoy Diagnostics; Hengrui Therapeutics; Innovent Biologics; QiLu Pharmaceutical; Top Alliance BioScience